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Use of Ultrasound to Assess the Response to Therapy for
Secondary Hyperparathyroidism
Mario Meola, MD, PhD,1,2 Ilaria Petrucci, MD,2 Elisa Colombini, MD,2 and
Giuliano Barsotti, MD2
Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease.
In SHPT, the biology of parathyroid cells changes significantly toward diffuse nodular hyperplasia. Currently,
diagnosis of SHPT is based on intact parathyroid hormone serum levels and parameters of mineral metabo-
lism. The morphologic diagnosis of SHPT relies on high-resolution ultrasonography with color Doppler imaging.
This report describes a maintenance hemodialysis patient with severe SHPT treated using conventional
therapy (phosphate binders and oral/intravenous vitamin D or analogues) and the subsequent addition of a
calcimimetic. The role of color Doppler ultrasonography in the diagnosis, clinical follow-up, and assessment of
therapeutic response of SHPT is discussed. This case suggests that the availability of calcimimetics has
changed the natural history of clinical SHPT and may change the therapeutic utility of parathyroidectomy. Use
of color Doppler ultrasonography further supports these therapeutic advances, allowing evaluation of the
morphologic and vascular changes in hyperplastic parathyroid glands and aiding clinical, pharmacologic, and
surgical strategies.
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Secondary hyperparathyroidism (SHPT) is a seri-
ous complication of chronic kidney disease and main-
tenance hemodialysis (HD) therapy. Hypocalcemia,
phosphate retention, and 1,25 dihydroxyvitamin D3
deficiency are the stimuli behind the synthesis and
release of parathyroid hormone (PTH).1,2 Loss of
renal mass results in persistent overstimulation of the
parathyroid glands, resulting in changes to their cell
biology, triggering cell hypertrophy-hyperplasia, and
leading to the selection of cell clones with decreased
calcium receptor and vitamin D receptor density.1
Long-term hyperstimulation of the parathyroid
glands produces glandular hyperplasia, which is at
first polyclonal, then monoclonal and nodular, pro-
gressing to a growth disorder (tertiary hyperparathy-
roidism).3 Nodular hyperplasia does not involve all
glands or affect all patients with chronic kidney dis-
ease equally; therefore, it can be assumed that un-
known genetic mechanisms may be involved.4,5
The identification of healthy parathyroid glands is
difficult. However, high-resolution ultrasonography
(US) with color Doppler imaging can be used to
localize hyperplastic glands. Color Doppler US is the
only technique that measures volumetric variations of
the hyperplastic glands and provides semiquantitative
parameters on glandular perfusion.6
In this report, we describe a maintenance HD
patient with severe SHPT treated using conventional
therapy (phosphate binders and oral/intravenous vita-
min D or analogues), then percutaneous ethanol injec-
Am J Kidney Dis. 2011;58(3):485-491tion, and finally the calcimimetic cinacalcet. We em-
phasize the role of color Doppler US to assess the
response to therapy for SHPT.
CASE REPORT
Clinical History and Initial LaboratoryData
We present the case of a 51-year-old woman undergoing mainte-
nance HD therapy since 1981 because of bladder exstrophy,
urinary obstructive, and reflux uropathy with recurrent urinary
tract infections. At 12 years of age, after multiple reconstructive
surgeries, serum creatinine was 2.5 mg/dL [221 mol/L]). Cystog-
raphy showed bilateral vesicoureteral reflux with grade IV hydro-
nephrosis. A ureteral-sigmoidal-cutaneostomy was performed, but
glomerular filtration rate progressively worsened. At the age of 22
years (serum creatinine, 12 mg/dL [1,060.8 mol/L], her estimated
glomerular filtration rate, calculated using the MDRD (Modifica-
tion of Diet in Renal Disease) Study equation, was 5 mL/min [0.08
mL/s], so she started maintenance HD treatment. In 1990, after 9
years of maintenance HD therapy and continuous oral therapy with
calcium carbonate, 4 g/d, serum calcium level was 11 mg/dL (2.64
mmol/L), serum phosphorus level was 4.9 mg/dL (1.58 mmol/L),
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Meola et alcalcium-phosphorous product was 49 mg2/dL2 (4.17 mmol2/L2),
intact PTH (iPTH) level was 611 pg/mL (611 ng/L), and alkaline
phosphatase level was 580 U/L.
ImagingStudies
In 1990, color Doppler US showed nodular hyperplasia of the
right inferior parathyroid gland. The gland measured 13  10 8
mm with a calculated volume of 543 mm3. In 1993, the volume of
the right inferior gland was 4,260 mm3, and a small left hy-
poechoic parathyroid with abnormal size (5 3 4 mm; volume,
31 mm3) became evident.
In 1994, color Doppler US showed a further increase in volume
of the right inferior parathyroid (23 19 20 mm; volume, 4,556
mm3) and the left gland (81 mm3). Subtraction scintigraphy
showed only hyperaccumulation of radiotracer near the right
inferior pole of the thyroid. From 1997 to 2003, both glands
increased in size (5,299 and 210 mm3) and an enlarged parathyroid
gland (65 mm3) was noted at the inferior pole of the left thyroid
lobe.
In January 2005, color Doppler US showed 4 hyperplastic
parathyroid glands. On the right side, the biggest gland was 22 
20 21 mm with a volume of 4,827 mm3 and appeared hypervas-
cularized. The second gland was in the superior mediastinum on
the right side and measured 9  7  5 mm with a volume of 164
mm3. On the left side, there were 2 parathyroid glands measuring
11 8 7 mm with a volume of 321 mm3 (superior) and 9 8
7 mm with a volume of 263 mm3 (inferior). Color Doppler showed
a hypervascularized pattern.Figure 1. Volumetric variations of the pa
486In 2006, color Doppler US showed a small volume increase in
the right inferior parathyroid gland due to cyst-like involutions and
widespread hypovascularization. The decrease in volume of the
other glands was not significant; however, intraglandular cyst-like
areas were noted in the bigger glands.
In 2007, color Doppler US showed wide cystic degeneration of
the largest gland, which appeared completely avascularized on
color Doppler. A decrease in volume and structural alterations of
the smaller gland (cystic areas and loss of color Doppler signal)
became more evident. To evaluate the functional significance of
the cyst-like involutions, technetium 99m (99mTc) methoxyisobu-
tyl isonitrile scintigraphy was performed. This showed an area of
early and late hyperaccumulation of tracer near the inferior pole of
the thyroid, but did not identify other glands.
In January 2010, color Doppler US showed that the right inferior
gland was 22 17 20 mm with a volume of 3,979 mm3, and its
morphologic and vascular patterns were unchanged. The mediasti-
nal gland was hyperechoic and measured 6  5  3 mm with a
volume of 47 mm3, the left superior gland was 9.9 5.3 4.2 mm
with a volume of 214 mm3 and absence of vascularization, and the
left inferior gland was no longer distinguishable (Fig 1).
Diagnosis
SHPT in a maintenance HD patient.
Clinical Follow-up
Laboratory data, imaging findings, and therapeutic interventions
are listed in Table 1.rathyroid glands from 1990 to 2010.
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Color Doppler US of the parathyroid glands has a
pivotal role in the diagnosis of SHPT, assessing the
severity of disease and evaluating response to medical
treatment. However, in clinical practice, color Dopp-
ler US is not commonly performed and SHPT diagno-
sis is based on iPTH serum levels and parameters of
mineral metabolism.
Because parathyroid glands normally are heavily
populated with adipose cells, they can be difficult to
distinguish from thyroid parenchyma even with the
use of high-resolution probes.7 However, cellular hy-
perplasia makes the glands diffusely hypoechoic and
easily detectable in the thyroid lodge. There is no set
size threshold above which a parathyroid gland is
identified as pathologic; however, if each of 2 diam-
eters is 5 mm, a hypoechoic gland is judged hyper-
Table 1. Clinical His
Year Clinical and Laboratory Findings Pa
1990 Ca, 11 mg/dL; P, 4.9 mg/dL; Ca  P, 49
mg2/dL2; ALP, 580 U/L; iPTH, 611 pg/
mL
RIG,
1990 9 mo after PEI treatment: ALP, 952 U/L;
iPTH, 795 pg/mL
1993 ALP, 500 U/L; iPTH, 700 pg/mL RIG,
1994-1996 ALP, 400-265 U/L; iPTH, 670-450 pg/mL RIG,
1997-2003 Ca, 12.3 mg/dL; P, 5.6 mg/dL; Ca  P,
68.8 mg2/dL2; ALP, 326 U/L; iPTH,
1,350 pg/mL; symptoms: itching,
severe osteoarticular/muscle pain,
lumbosacral tenderness, walking
difficulties
RIG,
mm
2005 Ca, 10.1 mg/dL; P, 6 mg/dL; Ca  P,
60.6 mg2/dL2; ALP, 740 U/L; iPTH,
1,480 pg/mL
RIG,
mm
26
for
2005 Ca, 10.5 mg/dL; P, 5 mg/dL; Ca  P,
52.5 mg2/dL2; ALP, 1,243 U/L; iPTH,
1,600 pg/mL
2010 Ca, 8.6 mg/dL; P, 5 mg/dL; Ca  P, 43
mg2/dL2; ALP, 316 U/L; iPTH, 360-400
pg/mL
RIG,
de
pa
(va
21
0);
Note: Conversion factors for units: serum Ca in mg/dL to mmol/
to mmol2/dL2,0.077. No conversion necessary for PTH in pg/m
Abbreviations and definitions: Al(OH)3, aluminum hydroxide; A
product; CaCO3, calcium carbonate; iPTH, intact parathyroid ho
superior parathyroid gland; P, phosphorus; PEI, percutaneous
mediastinic parathyroid gland; SHPT, secondary hyperparathyro
aVolume and (when applicable) vascular pattern assessed usin
bNo longer distinguishable.plastic8 (Fig 2). Glandular volume (in cubic millime-
Am J Kidney Dis. 2011;58(3):485-491ters) is calculated using the formula of an irregular
ellipsoid (4/3   ½ anteroposterior diameter  ½
laterolateral diameter ½ craniocaudal diameter).
The increase in glandular volume suggests in-
creased PTH secretion and worsening of SHPT.9
Studies that correlate glandular volume with histo-
logic features of the excised glands at parathyroidec-
tomy show that glands500 mm3 are affected mainly
by diffuse and polyclonal hyperplasia, whereas glands
500 mm3 are affected by monoclonal nodular hyper-
plasia in 80% of cases. Moreover, because there is
wide variation in glandular volume, the overall sensi-
tivity of color Doppler US in SHPT diagnosis is
74%-75% (50% in the localization of parathyroids
500 mm3 and90% in glands500 mm3).10
The ability to assess changes in glandular volume
gives color Doppler US a unique advantage over
f Patient With SHPT
roid Gland Imaginga Treatment Decision
mm3 PEI of the only hyperplastic
parathyroid gland detectable on US
0 mm3; LSG, 31 mm3 Vitamin D (4 g 3/wk); CaCO3
decreased to 2-3 g/d
6 mm3; LSG, 81 mm3 Oral calcitriol replaced by IV calcitriol,
1.5 g 3/wk; CaCO3 stopped;
Al(OH)3 added (3 tablets 2/wk)
9 mm3; LSG, 210
IG, 65 mm3
Calcitriol therapy interrupted due to
episodes of hypercalcemia and
hyperphosphatemia;
parathyroidectomy indicated, but
patient refused; calcitriol therapy
reintroduced
7 mm3; RMG, 164
SG, 321 mm3; LIG,
3; vascular pattern 3
Calcitriol replaced by IV paricalcitol (5
g 3/wk) associated with
sevelamer (4,800 mg/d) and
CaCO3 (2 g/d)
Cinacalcet (maximum dosage, 150
mg/d) added to conventional
therapy
9 mm3 (cystic
ration; vascular
0); RM, 47 mm3
ar pattern 0); LSG,
3 (vascular pattern
Cinacalcet (120 mg/d), paricalcitol (5
g 3/wk) associated with
sevelamer (4,800 mg/d) and
CaCO3 (2 g/d)
.2495; serum P in mg/dL to mmol/L,0.3229; CaP in mg2/dL2
ng/L.
lkaline phosphatase; Ca, calcium; Ca  P, calcium-phosphorus
e; IV, intravenous; LIG, left inferior parathyroid gland; LSG, left
nol injection; RIG, right inferior parathyroid gland; RMG, right
; US, ultrasonography.
lor Doppler US.tory o
rathy
543
4,26
4,55
5,29
3; L
4,82
3; L
3 mm
all
3,97
gene
ttern
scul
4 mm
LIGb
L,0
L and
LP, a
rmon
etha
idism
g coSPECT (single-photon emission computed tomogra-
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of vas
Meola et alphy)–scintigraphy, computed tomography, and mag-
netic resonance imaging.
The increase in parathyroid gland volume is associ-
ated with a widespread increase in vascularity, evident
histologically.11-13 Usually color Doppler distin-
guishes 3 different patterns,10 as shown in Fig 2D-F.
According to international guidelines, SHPT diag-
nosis is based on iPTH serum levels and parameters of
mineral metabolism. However, the optimal values for
iPTH in maintenance HD patients are still uncer-
tain,14,15 and hormone levels show great variability.16
Because levels are influenced by drug therapy, iPTH
level does not provide information for grading hyper-
plasia. Color Doppler US evaluates the degree of
hyperplasia and number of glands involved, complet-
ing the biochemical diagnosis. We routinely perform
color Doppler US of the parathyroid glands when
iPTH values are consistently 400 pg/mL (400
ng/L) and repeat this study annually in maintenance
HD patients to evaluate the progression of disease.
B-Mode parameters important for the assessment of
SHPT progression include: (1) the gland’s echogenic-
ity, (2) gland diameter17 and volume, (3) appearance
of anechoic areas with no vascularization suggesting
involutive cystic phenomena, and (4) presence of
Figure 2. Progression of parathyroid gland hyperplasia. (A) L
that makes the glands enlarged and diffusely hypoechoic (arr
hyperplasia is at first diffuse and polyclonal, then monoclonal and
a widespread increase in vascularity. Color Doppler distingu
hypovascularized glands with only a few color spots in the hilar/e
glands fed by an enlarged hilar artery that have a peripheral arc
common carotid; T, thyroid.fibrocalcifications.13
488In our case, nodular hyperplasia of a single gland
appeared after a long period of maintenance HD
therapy. Color Doppler US was used to perform
chemical ablation with percutaneous ethanol injec-
tion, but biochemical/morphologic results were poor.
Afterward, other hyperplastic glands appeared, show-
ing the slow but continuous progression of SHPT
despite oral/intravenous vitamin D treatments. At this
stage, the evidence of nodular hyperplasia on color
Doppler US, severity of SHPT, and refractoriness to
therapy with vitamin D/binders indicated the neces-
sity of parathyroidectomy, which was refused by the
patient.
The role of color Doppler US in the presurgical
evaluation of SHPT is very different from primary
hyperparathyroidism. The sensitivity of color Doppler
US in the localization of adenoma/carcinoma is very
high (90%-92%) for primary hyperparathyroidism,
similar to that of conventional parathyroidectomy
(93%-99%).18 In a patient with SHPT, the role of
imaging is less critical because parathyroidectomy is
performed using conventional cervicotomy. More-
over, because there is wide variation in glandular
volume and the overall sensitivity of color Doppler
US for SHPT is lower than for primary hyperparathy-
term hyperstimulation of parathyroid glands causes hyperplasia
, easily distinguishable in the thyroid lodge. (B, C) Glandular
lar. The increase in parathyroid gland volume is associated with
3 different patterns: (D) glands lacking Doppler signal, (E)
odular region (weak Doppler signal), and (F) hypervascularized
cularity and/or ray-like endonodular vessels. Abbreviations: Cc,ong-
ows)
nodu
ishes
ndonroidism, the role of color Doppler US therefore should
Am J Kidney Dis. 2011;58(3):485-491
Ultrasound in Secondary Hyperparathyroidismnot be to localize the glands, but instead to determine
surgical timing. Parathyroidectomy is indicated when
color Doppler US evidences one or more hyperplastic
glands 500 mm3, serum iPTH level is 700 pg/mL
(700 ng/L), and calcium, phosphorus, and calcium-
phosphorous product values are no longer controlled
using conventional therapy.19,20
Glandular volume is related directly to the number
of glands detected; it also may be highly variable and
not entirely correlated with iPTH level at greater than
a certain size/volume threshold. Calculated volume
shows a linear correlation with iPTH value only when
gland volume is 2,000 mm3 (ie, 2 g).8,21 This
observation suggests that the biggest glands tend to
disengage from receptor control mechanisms (ie, up-
regulation of calcium receptor and vitamin D recep-
tor) and grow independently.
In our patient, the combination of conventional
therapy and cinacalcet marked a reversal in the progres-
sion of disease: PTH serum levels were decreased,
mineral metabolism was stabilized, and color Doppler
US showed progressive changes in volume and vascu-
larization. The regression resembled a “chemical para-
thyroidectomy,” and 5 years after beginning therapy,
surgical parathyroidectomy was not necessary.
Figure 3. Right inferior
parathyroid gland of clinical
case before and after cina-
calcet therapy. (A) Before
cinacalcet therapy, diam-
eters were 22  20  21
mm (volume, 4,827 mm3)
and the gland was diffusely
hypoechoic. (B) The vascu-
lar pattern was rich (type 3)
and showed a vascular hi-
lum. T, thyroid. (C) After 2
years of cinacalcet com-
bined therapy, the gland
was 21  21  21 mm
(4,838 mm3) and color
Doppler ultrasonography
showed wide cystic degen-
eration (D) with disappear-
ance of vascularization. Ab-
breviation: T, thyroid.
Am J Kidney Dis. 2011;58(3):485-491Color Doppler US showed a volume decrease asso-
ciated with loss of vascular signal, progressing to
complete disappearance of vascularization in the big-
gest glands (500 mm3; Fig 3). Most glands involute
(cystic-like lesions; Fig 4), whereas glands 500
mm3 show a volume decrease accompanied by a
structural change toward hyperechogenicity, as if the
relationship between cellularity and stromal adipose
tissue had been reversed. This suggests that calcimi-
metic treatment modulates the biological response of
cells with uncontrolled proliferation through direct
stimulation of calcium receptor and vitamin D recep-
tor expression.18
In conclusion, if iPTH serum levels are constantly
400 pg/mL (400 ng/L), color Doppler US can be
performed to evaluate the presence of hyperplastic
glands and complete the clinical diagnosis. This can
be repeated once a year to evaluate disease progres-
sion. The availability of calcimimetics is changing the
natural history of SHPT and may change the therapeu-
tic utility of surgical parathyroidectomy. Use of color
Doppler US further supports these therapeutic ad-
vances, allowing evaluation of morphologic and vas-
cular changes in hyperplastic glands and aiding clini-
cal, pharmacologic, and surgical strategies.489
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